Accessibility Menu
Cardax logo

Cardax(OTC) CDXI

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year-99%
1 Month+0%
$0.00
+0%
+0.00Today
Cardax last closing stock price
MetricPriceDate
Last closeUSD 0.002026-06-01
Cardax stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-05-21
1 month+0%USD 0.002026-04-27
3 month-99%USD 0.002026-03-02
Year to date-99%USD 0.002025-12-29
1 year-99%USD 0.002025-05-14
3 year-99.91%USD 0.002023-05-16
5 year-100%USD 1.652021-06-01
Since inception-100%USD 610.002014-02-10

Cardax Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$500.71K

Net Income (TTM)

-$7.68M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

72.34 (High)

Price

$0.00

Volume

20

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

CDXI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardax

Cardax, Inc. is a biopharmaceutical company dedicated to developing nutritional supplements and pharmaceutical treatments targeting inflammation and oxidative stress. The company’s flagship product, ZanthoSyn, is an advanced supplement designed to enhance health and longevity through superior absorption of astaxanthin.

Products and Services
  • ZanthoSyn: A premium supplement for inflammation and health
  • CDX-101: A drug candidate for cardiovascular inflammation
  • CDX-301: A zeaxanthin-based treatment for macular degeneration
Growth Outlook
  • Expansion of online sales channels is anticipated to boost revenue
  • Ongoing development of CDX-101 and CDX-301 may enhance market position
  • Increasing awareness of inflammation-related health issues supports product demand
Financial Highlights
  • Recent quarterly revenue of $104,574 reflects ongoing market challenges
  • Trailing twelve months (TTM) gross profit margin stands at 63.6%
  • Net income for the latest quarter was -$1,820,403, indicating operational losses
Cardax, Inc. operates in the biotechnology sector, focusing on innovative solutions for chronic health issues. The company’s product portfolio includes both nutritional supplements and pharmaceutical candidates, which are positioned to address significant health concerns related to inflammation. The growth outlook is supported by the increasing prevalence of inflammation-related conditions and the potential for product expansion through online sales. Financially, the company has faced challenges, as indicated by recent revenue figures and net income losses. However, the gross profit margin suggests a solid foundation for future profitability as the company navigates its growth strategy.
AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Headquarters

Honolulu, HI 96822, US

CDXI Financials

Key Financial Metrics (TTM)

Gross Margin

63.61%

Operating Margin

-568.26%

Net Income Margin

-938.04%

Return on Equity

58.12%

Return on Capital

N/A

Return on Assets

-354.73%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

802.50K

Volume

20

Avg. Volume

1.048

Financials (TTM)

Gross Profit

$329.19K

Operating Income

-$2.93M

EBITDA

-$3.03M

Operating Cash Flow

-$1.56M

Capital Expenditure

-$7.76K

Free Cash Flow

-$1.57M

Cash & ST Invst.

$58.65K

Total Debt

$5.40M

Cardax Performance Analysis

Cardax sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22020-06-30-5.8%
Q32020-09-30-50.6%
Q42020-12-31193.4%
Q12021-03-31-46.4%
Cardax sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22020-06-30-73.9%
Q32020-09-3034.7%
Q42020-12-3123.8%
Q12021-03-31-27.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2021YOY CHG

Revenue

$104.57K

-26.8%

Gross Profit

$66.20K

-17.1%

Gross Margin

63.30%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

10

N/A

Net Income

-$1.82M

-25.5%

EBITDA

-$935.52K

-71.3%

Quarterly Fundamentals

Name
Q1 2021YOY CHG

Total Cash

$58.65K

+14.6%

Total Debt

$5.40M

+85.0%

Accounts Receivable

$36.75K

-64.5%

Inventory

$962.86K

-13.8%

Long Term Debt

$211.36K

-78.9%

Short Term Debt

$5.18M

+170.5%

Return on Assets

-3.55%

N/A

Return on Invested Capital

33.56%

N/A

Free Cash Flow

-$337.93K

+41.5%

Operating Cash Flow

-$337.11K

+40.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MODCModern Technology Corp.
$0.00+0.00%
NBRVFNabriva Therapeutics plc
$0.00+0.00%
ELOXEloxx Pharmaceuticals, Inc.
$12.24-4.45%
NEXINexImmune, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About CDXI

What is the current price of Cardax?

Cardax is trading at $0.00 per share.

What is the 52-week range for Cardax?

Over the past 52 weeks, Cardax has traded between $0.00 and $0.00.

How much debt does Cardax have?

Cardax total debt is unavailable.

How much cash does Cardax have on hand?

Cardax does not have cash on hand data available.

What is Cardax’s dividend yield?

Cardax does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.